<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="discussion"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Public Health</journal-id><journal-id journal-id-type="iso-abbrev">Front Public Health</journal-id><journal-id journal-id-type="publisher-id">Front. Public Health</journal-id><journal-title-group><journal-title>Frontiers in Public Health</journal-title></journal-title-group><issn pub-type="epub">2296-2565</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7314948</article-id><article-id pub-id-type="doi">10.3389/fpubh.2020.00309</article-id><article-categories><subj-group subj-group-type="heading"><subject>Public Health</subject><subj-group><subject>Opinion</subject></subj-group></subj-group></article-categories><title-group><article-title>The COVID-19 Diagnostic Technology Landscape: Efficient Data Sharing Drives Diagnostic Development</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aguiar</surname><given-names>Eric R. G. R.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/486067/overview"/></contrib><contrib contrib-type="author"><name><surname>Navas</surname><given-names>Jes&#x000fa;s</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/913824/overview"/></contrib><contrib contrib-type="author"><name><surname>Pacheco</surname><given-names>Luis G. C.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/45021/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Biological Sciences, Center of Biotechnology and Genetics, State University of Santa Cruz (UESC)</institution>, <addr-line>Ilh&#x000e9;us</addr-line>, <country>Brazil</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Molecular Biology, Universidad de Cantabria</institution>, <addr-line>Santander</addr-line>, <country>Spain</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Biotechnology, Institute of Health Sciences, Federal University of Bahia (UFBA)</institution>, <addr-line>Salvador</addr-line>, <country>Brazil</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Zisis Kozlakidis, International Agency for Research on Cancer (IARC), France</p></fn><fn fn-type="edited-by"><p>Reviewed by: Na Hong, Digital China Health Technologies Co. Ltd, China</p></fn><corresp id="c001">*Correspondence: Luis G. C. Pacheco <email>luis.pacheco@ufba.br</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Public Health</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>6</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>8</volume><elocation-id>309</elocation-id><history><date date-type="received"><day>14</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>08</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Aguiar, Navas and Pacheco.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Aguiar, Navas and Pacheco</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><kwd-group><kwd>COVID-19</kwd><kwd>diagnostics</kwd><kwd>Point-of-care (POC)</kwd><kwd>data sharing</kwd><kwd>molecular diagnosis</kwd><kwd>immunoassay</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico<named-content content-type="fundref-id">10.13039/501100003593</named-content></funding-source></award-group><award-group><funding-source id="cn002">Minist&#x000e9;rio da Ci&#x000ea;ncia, Tecnologia, Inova&#x000e7;&#x000f5;es e Comunica&#x000e7;&#x000f5;es<named-content content-type="fundref-id">10.13039/501100011875</named-content></funding-source></award-group><award-group><funding-source id="cn003">Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior<named-content content-type="fundref-id">10.13039/501100002322</named-content></funding-source></award-group><award-group><funding-source id="cn004">Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado da Bahia<named-content content-type="fundref-id">10.13039/501100006181</named-content></funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="0"/><equation-count count="0"/><ref-count count="26"/><page-count count="4"/><word-count count="2712"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Since the first case descriptions in December 2019, the COVID-19 pandemic has prompted the development of diagnostic technologies at an unprecedented pace, and the pattern of collaborative scientific data sharing during this period has followed a similar path. A recent bibliometric study demonstrated that the research publication response to the COVID-19 pandemic was much more effective than in other recent epidemic events, namely the 2015&#x02013;16 Zika virus epidemic and the 2014&#x02013;16 Ebola virus outbreak in West Africa (<xref rid="B1" ref-type="bibr">1</xref>). Concerning only preprint publications, there were over 2,500 articles related to COVID-19 in the first 4 months of the pandemic, as opposed to only 88 articles in total related to both the Zika and Ebola viruses in the same epidemiological periods. Additionally, by the end of April, the total number of COVID-19 publications, including preprints and peer-reviewed articles, had already surpassed 16,000 (<xref rid="B1" ref-type="bibr">1</xref>). When we searched PubMed specifically for scientific publications related to COVID-19 diagnostics (search terms: COVID-19 AND Diagnostics), it returned at least 930 specific papers in the first 5 months of the COVID-19 epidemic period (limited to December 2019&#x02013;April 2020), while a similar search for Zika virus retrieved only nine publications related to diagnostics in the same time period (limited to March 2015&#x02013;July 2015). Other recent publications have also discussed the efficiency of open data sharing during the early part of the COVID-19 pandemic, particularly of epidemiological and diagnostic data, and how it contributed to early interventions (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>).</p><p>The speed by which viral genomic sequences were made publicly available during the COVID-19 pandemic also demonstrates the fast pace of data sharing during the period. As early as December 31, 2019, 19 genomic sequences of the SARS-CoV-2 virus were already available through the GISAID database (<ext-link ext-link-type="uri" xlink:href="https://www.gisaid.org">gisaid.org</ext-link>), which now has over 40,000 viral genome sequences shared by laboratories around the globe. As a comparison, during the Ebola virus outbreak, it took nearly 3 years for the number of sequenced viral genomes to reach 1,500 sequences (<xref rid="B4" ref-type="bibr">4</xref>). The early availability of SARS-CoV-2 genomic sequences contributed to the rapid development of the gold standard molecular diagnostic assays for COVID-19, based on reverse-transcription polymerase chain reaction (RT-qPCR), made available by the World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC), still in early 2020 (<xref rid="B5" ref-type="bibr">5</xref>&#x02013;<xref rid="B7" ref-type="bibr">7</xref>). Additionally, it also contributed to the development of streamlined protocols for complete viral genome sequencing and analysis (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>) and of lab-based serology assays that use recombinantly-produced SARS-CoV-2 proteins (<xref rid="B10" ref-type="bibr">10</xref>) (<xref ref-type="fig" rid="F1">Figure 1A</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>The COVID-19 diagnostic technology landscape. <bold>(A)</bold> A (non-exhaustive) list of the current and emerging technologies for laboratory-based or decentralized (near or at the point-of-care) COVID-19 diagnosis. Methods for clinical diagnosis of COVID-19, such as chest computed tomography, are discussed elsewhere (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B11" ref-type="bibr">11</xref>). *Disambiguation: despite being frequently used in the COVID-19 context, the abbreviation RT-PCR is more appropriate to the traditional method of reverse-transcription PCR. For real-time (quantitative) reverse-transcription PCR, such as in SARS-CoV-2 detection, it is more appropriate to use RT-qPCR or rtRT-PCR. FDA EUA, US Food and Drug Administration Emergency Use Authorization (EUA); PoC, point-of-care; NAT, nucleic acid test. <bold>(B)</bold> Categories of commercially manufactured COVID-19 diagnostic tests, as of late Apr 2020. <bold>(C)</bold> Regulatory status of the available tests. EUA, Emergency Use Authorization; CE-IVD, Conformit&#x000e9; Europ&#x000e9;enne (EU certification)-<italic>in vitro</italic> diagnostics; RUO, research use only. <bold>(D)</bold> Major technologies used in current point-of-care diagnostic tests for COVID-19.</p></caption><graphic xlink:href="fpubh-08-00309-g0001"/></fig></sec><sec id="s2"><title>Rapid Data Sharing Contributed To Development and Validation of Covid-19 Diagnostics</title><p>A good example demonstrating how rapid data sharing contributed to the development of diagnostics during the COVID-19 pandemic is shown by the first RT-qPCR assay design developed by researchers from the Charit&#x000e9; &#x02013; Universit&#x000e4;tsmedizin Berlin Institute of Virology in Germany (<xref rid="B12" ref-type="bibr">12</xref>). The first SARS-CoV-2 viral genome sequence was made publicly available for immediate public health support as soon as 10 days after official reporting of the early cases of atypical pneumonia in China to the WHO. Only 3 days later (on January 13, 2020), the first RT-qPCR assay was made available to the international community. A few days later, positive controls were already available through the European Virus Archive (EVAg) repository (<xref rid="B13" ref-type="bibr">13</xref>). Soon after, on February 4, 2020, the US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) to the CDC's 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. It did not take long for new studies describing SARS-CoV-2 viral load kinetics in different samples to be published for the different genomic targets (N, E, and RdRP), and this contributed to improvements in diagnostic protocols early in the epidemic. Compared to Zika virus epidemic, it was only nearly 1 year after first case descriptions in Brazil that the US FDA issued an EUA for the Trioplex assay on March 17, 2016.</p><p>The widespread adoption of preprint servers (such as <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org">medrxiv.org</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org">biorxiv.org</ext-link>) for sharing research data before peer review has also allowed rapid publication of studies evaluating the performances of different diagnostic technologies and has contributed to a clearer understanding of emerging technologies that will potentially aid in the diagnosis and surveillance of COVID-19 in the near future (<xref ref-type="fig" rid="F1">Figure 1A</xref>). Different studies have demonstrated that preprint publications were underutilized during the Zika and Ebola virus epidemics, despite being important tools for accelerating scientific development during disease outbreaks (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B14" ref-type="bibr">14</xref>). Now, COVID-19 related preprint publications have permitted foreseeing emerging roles for technologies based on loop-mediated isothermal amplification (LAMP) and CRISPR-based diagnostics, as these technologies are indeed appearing now in peer-reviewed publications and starting to reach commercial applications. In an interesting recent development, for example, isothermal amplification by reverse-transcription (RT)-LAMP was combined with specific CRISPR/Cas12 detection of SARS-CoV-2 amplified targets and with visual readout by lateral flow assay (<xref rid="B15" ref-type="bibr">15</xref>).</p></sec><sec id="s3"><title>The Covid-19 Point-of-Care Diagnostic Technology Landscape</title><p>Now, we can easily follow the development of new COVID-19 diagnostic technology into commercial products due to data sharing initiatives, such as the Foundation for Innovative New Diagnostics (FIND; <ext-link ext-link-type="uri" xlink:href="https://www.finddx.org/covid-19/">finddx.org/covid-19/</ext-link>) and 360 Dx coronavirus test tracker (<ext-link ext-link-type="uri" xlink:href="https://www.360dx.com">360dx.com</ext-link>). From data made available on over 590 COVID-19 diagnostic tests (as of April 24, 2020), we can have a clear view of the point-of-care (PoC) diagnostic technology landscape (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Although the numbers of commercially manufactured COVID-19 molecular tests and immunoassays are similar, there is clearly a higher proportion of decentralized tests that are based on immunoassays when compared to molecular methods (<xref ref-type="fig" rid="F1">Figure 1B</xref>). This is probably due to the technological maturity of colloidal-gold immunochromatographic assays. Conversely, the greater number of lab-based commercial molecular tests for COVID-19 is due to the high number of companies offering RT-qPCR based kits (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Regarding regulatory status, there is a high proportion of CE-marked PoC tests that comply with the relevant European Union regulations (Directive 98/79/EC on <italic>in vitro</italic> diagnostics), although this does not necessarily mean that these tests are commercially available in Europe (<xref ref-type="fig" rid="F1">Figure 1C</xref>). Additionally, novel EUAs for COVID-19 tests are being granted in a continuous basis by regulatory agencies worldwide, including the US FDA (<ext-link ext-link-type="uri" xlink:href="https://www.fda.gov">fda.gov</ext-link>) and the Brazilian ANVISA (<ext-link ext-link-type="uri" xlink:href="http://portal.anvisa.gov.br/coronavirus">http://portal.anvisa.gov.br/coronavirus</ext-link>).</p><p>As of late April 2020, the WHO still did not recommend the use of PoC rapid immunodiagnostic tests (RDTs) for patient care and public health decision-making in the COVID-19 context (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). However, most of the commercially available tests to date are in fact based on lateral flow immunoassay (LFIA) technologies for detecting SARS-CoV-2 antigens or human IgM/IgG antibodies (<xref ref-type="fig" rid="F1">Figure 1D</xref>). Regarding PoC or near-PoC commercially manufactured molecular tests, two technological strategies are clear: (i) methods that provide simplified workflows for nucleic acid amplification tests (NAATs); and (ii) methods based on isothermal amplification by LAMP. In the former category, tried-and-tested diagnostic platforms with simplified sample-to-results workflows have already been introduced by major companies, such as the Xpert Xpress SARS-CoV-2 test (Cepheid) and the ID Now COVID-19 assay (Abbott Diagnostics).</p></sec><sec sec-type="conclusions" id="s4"><title>Conclusion</title><p>The rapid development of diagnostic technology is an essential component of an epidemic preparedness strategic plan (<xref rid="B18" ref-type="bibr">18</xref>). Accordingly, the technological landscape of the development of COVID-19 diagnostics is rapidly evolving, with new information being generated on a daily basis. Different platforms for open and fast data sharing have been contributing to this rapid diagnostic development, that include: fast availability of genomic data in public sequence repositories (e.g., <ext-link ext-link-type="uri" xlink:href="https://www.gisaid.org">gisaid.org</ext-link>); open collaboration in preliminary data analysis using science community blogs and discussion forums (e.g., <ext-link ext-link-type="uri" xlink:href="https://virological.org/">virological.org</ext-link>); publication of periodic reports by universities and international organizations (e.g., the WHO); real-time sharing of diagnostic validation results (e.g., <ext-link ext-link-type="uri" xlink:href="https://www.finddx.org">finddx.org</ext-link>); and particularly the use of preprint servers for early publication of research studies (e.g., medRxiv and bioRxiv). Recent studies have shown that these fast publication platforms are driving much of the debate about the COVID-19 pandemic, despite the intrinsic limitations associated with the unregulated sharing of research results at such fast pace (<xref rid="B19" ref-type="bibr">19</xref>). Therefore, to ensure the integrity and quality of rapidly shared studies, the research community is already putting into practice several control mechanisms, at various levels (<xref rid="B20" ref-type="bibr">20</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>). From researcher-led initiatives, that include the creation of open peer-review platforms for improving the quality of COVID-19-related preprints (<xref rid="B21" ref-type="bibr">21</xref>), to publisher-led initiatives, such as the fast peer-review of research studies previously posted to non-peer reviewed platforms, these mechanisms will altogether contribute to guarantee the credibility of speedy information delivery during the pandemic (<xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>).</p><p>This opinion paper was not meant to present exhaustive information on COVID-19 diagnosis, but rather to make an overview of currently available technologies in the academic and commercial settings for laboratory and PoC testing. For excellent reviews on strategies for COVID-19 diagnosis, we refer the readers to Cheng et al. (<xref rid="B6" ref-type="bibr">6</xref>), Tang et al. (<xref rid="B7" ref-type="bibr">7</xref>), and Udugama et al. (<xref rid="B11" ref-type="bibr">11</xref>). Besides, up-to-date information on COVID-19 diagnostic technology can be found at the following sources:</p><list list-type="bullet"><list-item><p>WHO Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans (<xref rid="B23" ref-type="bibr">23</xref>)</p></list-item><list-item><p>FIND: COVID-19 Diagnostics Resource Center (<xref rid="B24" ref-type="bibr">24</xref>)</p></list-item><list-item><p>U.S. FDA Coronavirus Disease 2019 (COVID-19) (<xref rid="B25" ref-type="bibr">25</xref>).</p></list-item></list><p>As new COVID-19 diagnostic technologies are introduced, studies aimed at validating their usefulness in clinical settings will be of crucial importance (<xref rid="B26" ref-type="bibr">26</xref>). In this sense, collaborative data sharing on SARS-CoV-2 diagnostic performance evaluation, such as the initiatives led by FIND (<xref rid="B24" ref-type="bibr">24</xref>) and the WHO, will contribute to rapid adoption of new diagnostic technology and will inform public health decisions on a global scale.</p></sec><sec id="s5"><title>Author Contributions</title><p>EA, JN, and LP conceived the study. EA and LP collected data and prepared data presentation. All authors wrote, reviewed, and approved the final version of the manuscript.</p></sec><sec id="s6"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> Work at the Brazilian groups was partially funded by grants from MCTIC, CNPq, CAPES, and FAPESB. LP was recipient of a research fellowship from CNPq.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>N</given-names></name><name><surname>Brierley</surname><given-names>L</given-names></name><name><surname>Dey</surname><given-names>G</given-names></name><name><surname>Polka</surname><given-names>JK</given-names></name><name><surname>P&#x000e1;lfy</surname><given-names>M</given-names></name><name><surname>Coates</surname><given-names>JA</given-names></name></person-group>
<article-title>Preprinting a pandemic: the role of preprints in the COVID-19 pandemic</article-title>. <source>bioRxiv [Preprint]</source>. <pub-id pub-id-type="doi">10.1101/2020.05.22.111294</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moorthy</surname><given-names>V</given-names></name><name><surname>Henao Restrepo</surname><given-names>AM</given-names></name><name><surname>Preziosi</surname><given-names>M-P</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name></person-group>. <article-title>Data sharing for novel coronavirus (COVID-19)</article-title>. <source>Bull World Health Organ.</source> (<year>2020</year>) <volume>98</volume>:<fpage>150</fpage>. <pub-id pub-id-type="doi">10.2471/BLT.20.251561</pub-id><?supplied-pmid 32132744?><pub-id pub-id-type="pmid">32132744</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Kraemer</surname><given-names>MUG</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Gutierrez</surname><given-names>B</given-names></name><name><surname>Mekaru</surname><given-names>S</given-names></name><name><surname>Sewalk</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Open access epidemiological data from the COVID-19 outbreak</article-title>. <source>Lancet Infect. Diseases.</source> (<year>2020</year>) <volume>20</volume>:<fpage>534</fpage>. <pub-id pub-id-type="doi">10.1016/S1473-30992030119-5</pub-id><?supplied-pmid 32087115?><pub-id pub-id-type="pmid">32087115</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>C</given-names></name></person-group>. <article-title>How countries are using genomics to help avoid a second coronavirus wave</article-title>. <source>Nature</source>. (<year>2020</year>) <volume>582</volume>:<fpage>19</fpage>. <pub-id pub-id-type="doi">10.1038/d41586-020-01573-5</pub-id><?supplied-pmid 32488156?><pub-id pub-id-type="pmid">32488156</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheridan</surname><given-names>C</given-names></name></person-group>. <article-title>Fast, portable tests come online to curb coronavirus pandemic</article-title>. <source>Nat Biotechnol.</source> (<year>2020</year>) <volume>38</volume>:<fpage>515</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/d41587-020-00010-2</pub-id><?supplied-pmid 32203294?><pub-id pub-id-type="pmid">32203294</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>MP</given-names></name><name><surname>Papenburg</surname><given-names>J</given-names></name><name><surname>Desjardins</surname><given-names>M</given-names></name><name><surname>Kanjilal</surname><given-names>S</given-names></name><name><surname>Quach</surname><given-names>C</given-names></name><name><surname>Libman</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Diagnostic testing for severe acute respiratory syndrome&#x02013;related coronavirus 2: a narrative review</article-title>. <source>Ann Internal Med.</source> (<year>2020</year>) <volume>172</volume>:<fpage>726</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.7326/M20-1301</pub-id><?supplied-pmid 32282894?><pub-id pub-id-type="pmid">32282894</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y-W</given-names></name><name><surname>Schmitz</surname><given-names>JE</given-names></name><name><surname>Persing</surname><given-names>DH</given-names></name><name><surname>Stratton</surname><given-names>CW</given-names></name></person-group>. <article-title>Laboratory diagnosis of COVID-19: current issues and challenges</article-title>. <source>J Clin Microbiol.</source> (<year>2020</year>) <volume>58</volume>:<fpage>e00512</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.00512-20</pub-id><?supplied-pmid 32245835?><pub-id pub-id-type="pmid">32245835</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname><given-names>GS</given-names></name><name><surname>Sardi</surname><given-names>SI</given-names></name><name><surname>Falcao</surname><given-names>MB</given-names></name><name><surname>Belitardo</surname><given-names>EMMA</given-names></name><name><surname>Rocha</surname><given-names>DJPG</given-names></name><name><surname>Rolo</surname><given-names>CA</given-names></name><etal/></person-group>. <article-title>Ion torrent-based nasopharyngeal swab metatranscriptomics in COVID-19</article-title>. <source>J Virol Methods.</source> (<year>2020</year>) <volume>282</volume>:<fpage>113888</fpage>. <pub-id pub-id-type="doi">10.1016/j.jviromet.2020.113888</pub-id><?supplied-pmid 32445875?><pub-id pub-id-type="pmid">32445875</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients</article-title>. <source>Clin Infect Diseases</source>. (<year>2020</year>) ciaa203. <pub-id pub-id-type="doi">10.1093/cid/ciaa203</pub-id>. [Epub ahead of print].<?supplied-pmid 32129843?></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Kou</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2</article-title>. <source>J Clin Microbiol.</source> (<year>2020</year>) <volume>58</volume>:<fpage>e00461</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.00461-20</pub-id><?supplied-pmid 32229605?><pub-id pub-id-type="pmid">32229605</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udugama</surname><given-names>B</given-names></name><name><surname>Kadhiresan</surname><given-names>P</given-names></name><name><surname>Kozlowski</surname><given-names>HN</given-names></name><name><surname>Malekjahani</surname><given-names>A</given-names></name><name><surname>Osborne</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>VYC</given-names></name><etal/></person-group>. <article-title>Diagnosing COVID-19: the disease and tools for detection</article-title>. <source>ACS Nano.</source> (<year>2020</year>) <volume>14</volume>:<fpage>3822</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c02624</pub-id><?supplied-pmid 32223179?><pub-id pub-id-type="pmid">32223179</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Landt</surname><given-names>O</given-names></name><name><surname>Kaiser</surname><given-names>M</given-names></name><name><surname>Molenkamp</surname><given-names>R</given-names></name><name><surname>Meijer</surname><given-names>A</given-names></name><name><surname>Chu</surname><given-names>DK</given-names></name><etal/></person-group>
<article-title>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</article-title>. <source>Eurosurveillance.</source> (<year>2020</year>) 25:2000045. <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.3.2000045</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romette</surname><given-names>JL</given-names></name><name><surname>Prat</surname><given-names>CM</given-names></name><name><surname>Gould</surname><given-names>EA</given-names></name><name><surname>de Lamballerie</surname><given-names>X</given-names></name><name><surname>Charrel</surname><given-names>R</given-names></name><name><surname>Coutard</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>The European virus archive goes global: a growing resource for research</article-title>. <source>Antiviral Res.</source> (<year>2018</year>) <volume>158</volume>:<fpage>127</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2018.07.017</pub-id><?supplied-pmid 30059721?><pub-id pub-id-type="pmid">30059721</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>MA</given-names></name><name><surname>Reich</surname><given-names>NG</given-names></name><name><surname>Meyers</surname><given-names>LA</given-names></name><name><surname>Lipsitch</surname><given-names>M</given-names></name></person-group>. <article-title>Preprints: an underutilized mechanism to accelerate outbreak science</article-title>. <source>PLoS Med.</source> (<year>2018</year>) <volume>15</volume>:<fpage>e1002549</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1002549</pub-id><?supplied-pmid 29614073?><pub-id pub-id-type="pmid">29614073</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Broughton</surname><given-names>JP</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Fasching</surname><given-names>CL</given-names></name><name><surname>Servellita</surname><given-names>V</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>CRISPR&#x02013;Cas12-based detection of SARS-CoV-2</article-title>. <source>Nat Biotechnol</source>. (<year>2020</year>). <pub-id pub-id-type="doi">10.1038/s41587-020-0513-4</pub-id>. [Epub ahead of print].<?supplied-pmid 32300245?></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group>
<source>Laboratory Testing Strategy Recommendations for COVID-19: Interim Guidance</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name> (<year>2020</year>).</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group>
<article-title>Advice on the Use of Point-of-Care immunodiagnostic Tests for COVID-19: Scientific Brief</article-title>. <publisher-loc>Geneva: World Health Organization</publisher-loc> (<year>2020</year>).</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peeling</surname><given-names>RW</given-names></name><name><surname>Murtagh</surname><given-names>M</given-names></name><name><surname>Olliaro</surname><given-names>PL</given-names></name></person-group>. <article-title>Epidemic preparedness: why is there a need to accelerate the development of diagnostics?</article-title>
<source>Lancet Infect Diseases.</source> (<year>2019</year>) <volume>19</volume>:<fpage>e172</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-30991830594-2</pub-id><?supplied-pmid 30551872?><pub-id pub-id-type="pmid">30551872</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majumder</surname><given-names>MS</given-names></name><name><surname>Mandl</surname><given-names>KD</given-names></name></person-group>. <article-title>Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility</article-title>. <source>Lancet Global Health.</source> (<year>2020</year>) <volume>8</volume>:<fpage>e627</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/S2214-109X2030113-3</pub-id><?supplied-pmid 32220289?><pub-id pub-id-type="pmid">32220289</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Conroy</surname><given-names>G</given-names></name></person-group>
<article-title>Three Online Tools Aimed at Improving Preprints</article-title>. (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.natureindex.com/news-blog/three-online-tools-aimed-at-improving-preprints">https://www.natureindex.com/news-blog/three-online-tools-aimed-at-improving-preprints</ext-link> (accessed June 7, 2020).</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>MA</given-names></name><name><surname>Saderi</surname><given-names>D</given-names></name></person-group>. <article-title>Open peer-review platform for COVID-19 preprints</article-title>. <source>Nature.</source> (<year>2020</year>) <volume>579</volume>:<fpage>29</fpage>. <pub-id pub-id-type="doi">10.1038/d41586-020-00613-4</pub-id><?supplied-pmid 32127711?><pub-id pub-id-type="pmid">32127711</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>E</given-names></name></person-group>. <article-title>Will the pandemic permanently alter scientific publishing?</article-title>
<source>Nature. (2</source>020) <volume>582</volume>:<fpage>167</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/d41586-020-01520-4</pub-id><?supplied-pmid 32504015?><pub-id pub-id-type="pmid">32504015</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group>
<source>Coronavirus Disease (COVID-19) Technical Guidance: Laboratory Testing for 2019-nCoV in Humans</source>. (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance</ext-link> (accessed June 2, 2020).</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>SARS-CoV-2 diagnostics:</collab></person-group>
<source>Performance Data</source>. (<year>2020</year>). FIND Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.finddx.org/covid-19/dx-data/">https://www.finddx.org/covid-19/dx-data/</ext-link> (accessed June 2, 2020)</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>FDA</collab></person-group>
<article-title>Coronavirus Disease 2019 (COVID-19)</article-title>. <source>FDA</source>. (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19">https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19</ext-link> (accessed June 2, 2020).</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Green</surname><given-names>K</given-names></name><name><surname>Graziadio</surname><given-names>S</given-names></name><name><surname>Turner</surname><given-names>P</given-names></name><name><surname>Fanshawe</surname><given-names>T</given-names></name><name><surname>Allen</surname><given-names>J</given-names></name></person-group>
<article-title>Molecular and antibody point-of-care tests to support the screening, diagnosis and monitoring of COVID-19</article-title>. <publisher-loc>Oxford, UK: Oxford COVID-19 Evidence Service</publisher-loc> (<year>2020</year>).</mixed-citation></ref></ref-list></back></article>